JP2017523784A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017523784A5 JP2017523784A5 JP2017505792A JP2017505792A JP2017523784A5 JP 2017523784 A5 JP2017523784 A5 JP 2017523784A5 JP 2017505792 A JP2017505792 A JP 2017505792A JP 2017505792 A JP2017505792 A JP 2017505792A JP 2017523784 A5 JP2017523784 A5 JP 2017523784A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence shown
- amino acid
- acid sequence
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 134
- 108091008874 T cell receptors Proteins 0.000 claims description 97
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 97
- 210000004027 cell Anatomy 0.000 claims description 91
- 102000014914 Carrier Proteins Human genes 0.000 claims description 73
- 108091008324 binding proteins Proteins 0.000 claims description 73
- 108091033319 polynucleotide Proteins 0.000 claims description 72
- 239000002157 polynucleotide Substances 0.000 claims description 72
- 102000040430 polynucleotide Human genes 0.000 claims description 72
- 239000002773 nucleotide Substances 0.000 claims description 58
- 125000003729 nucleotide group Chemical group 0.000 claims description 58
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 32
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 108010081208 RMFPNAPYL Proteins 0.000 claims description 17
- 201000011510 cancer Diseases 0.000 claims description 15
- 239000013604 expression vector Substances 0.000 claims description 13
- 239000000427 antigen Substances 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 12
- 210000000987 immune system Anatomy 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 208000035475 disorder Diseases 0.000 claims description 11
- 230000003463 hyperproliferative effect Effects 0.000 claims description 11
- 206010009944 Colon cancer Diseases 0.000 claims description 10
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 10
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 10
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 10
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 10
- 208000021668 chronic eosinophilic leukemia Diseases 0.000 claims description 10
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 8
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims description 8
- 108010075704 HLA-A Antigens Proteins 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 5
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 5
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 201000009030 Carcinoma Diseases 0.000 claims description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims description 5
- 206010014733 Endometrial cancer Diseases 0.000 claims description 5
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 5
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 5
- 208000009849 Female Genital Neoplasms Diseases 0.000 claims description 5
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 5
- 206010066476 Haematological malignancy Diseases 0.000 claims description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 208000034578 Multiple myelomas Diseases 0.000 claims description 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 206010038389 Renal cancer Diseases 0.000 claims description 5
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 5
- 206010039491 Sarcoma Diseases 0.000 claims description 5
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 5
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 5
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 5
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 5
- 210000001130 astrocyte Anatomy 0.000 claims description 5
- 201000009036 biliary tract cancer Diseases 0.000 claims description 5
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 5
- 210000000988 bone and bone Anatomy 0.000 claims description 5
- 201000010881 cervical cancer Diseases 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 5
- 210000004443 dendritic cell Anatomy 0.000 claims description 5
- 239000012636 effector Substances 0.000 claims description 5
- 201000004101 esophageal cancer Diseases 0.000 claims description 5
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 210000004602 germ cell Anatomy 0.000 claims description 5
- 208000005017 glioblastoma Diseases 0.000 claims description 5
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 5
- 201000010985 invasive ductal carcinoma Diseases 0.000 claims description 5
- 201000010982 kidney cancer Diseases 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 5
- 210000000822 natural killer cell Anatomy 0.000 claims description 5
- 201000008968 osteosarcoma Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 5
- 201000000849 skin cancer Diseases 0.000 claims description 5
- 210000004872 soft tissue Anatomy 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 230000002381 testicular Effects 0.000 claims description 5
- 201000002510 thyroid cancer Diseases 0.000 claims description 5
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
- 206010046766 uterine cancer Diseases 0.000 claims description 5
- 208000037965 uterine sarcoma Diseases 0.000 claims description 5
- 239000013598 vector Substances 0.000 claims description 5
- 230000014509 gene expression Effects 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims description 4
- 108020004705 Codon Proteins 0.000 claims description 3
- 239000013603 viral vector Substances 0.000 claims description 3
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 210000000265 leukocyte Anatomy 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 210000003515 double negative t cell Anatomy 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 108020001580 protein domains Proteins 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 31
- 108090000695 Cytokines Proteins 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 102100022748 Wilms tumor protein Human genes 0.000 description 4
- 230000001400 myeloablative effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 101000621309 Homo sapiens Wilms tumor protein Proteins 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 231100000782 microtubule inhibitor Toxicity 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462033045P | 2014-08-04 | 2014-08-04 | |
| US62/033,045 | 2014-08-04 | ||
| US201562164783P | 2015-05-21 | 2015-05-21 | |
| US62/164,783 | 2015-05-21 | ||
| PCT/US2015/042986 WO2016022400A1 (en) | 2014-08-04 | 2015-07-30 | T cell immunotherapy specific for wt-1 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018142600A Division JP2018183175A (ja) | 2014-08-04 | 2018-07-30 | Ｗｔ−１に特異的なｔ細胞免疫治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017523784A JP2017523784A (ja) | 2017-08-24 |
| JP2017523784A5 true JP2017523784A5 (enExample) | 2018-09-06 |
| JP6712261B2 JP6712261B2 (ja) | 2020-06-24 |
Family
ID=53901124
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017505792A Active JP6712261B2 (ja) | 2014-08-04 | 2015-07-30 | Ｗｔ−１に特異的なｔ細胞免疫治療 |
| JP2018142600A Pending JP2018183175A (ja) | 2014-08-04 | 2018-07-30 | Ｗｔ−１に特異的なｔ細胞免疫治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018142600A Pending JP2018183175A (ja) | 2014-08-04 | 2018-07-30 | Ｗｔ−１に特異的なｔ細胞免疫治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10538572B2 (enExample) |
| EP (1) | EP3177314B1 (enExample) |
| JP (2) | JP6712261B2 (enExample) |
| CN (1) | CN107074970B (enExample) |
| CA (1) | CA2956545A1 (enExample) |
| ES (1) | ES2841274T3 (enExample) |
| WO (1) | WO2016022400A1 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016011567A2 (pt) * | 2013-11-22 | 2017-10-24 | Hutchinson Fred Cancer Res | receptores de célula t humana de alta afinidade geneticamente modificados. |
| HK1246317A1 (zh) | 2015-03-05 | 2018-09-07 | Fred Hutchinson Cancer Center | 免疫调节融合蛋白及其用途 |
| US10975436B2 (en) | 2016-01-05 | 2021-04-13 | Diamir, Llc | Methods of using miRNA from bodily fluids for diagnosis and monitoring of neurodevelopmental disorders |
| SG11201808797XA (en) | 2016-04-08 | 2018-11-29 | Immunocore Ltd | T cell receptors |
| US10188749B2 (en) | 2016-04-14 | 2019-01-29 | Fred Hutchinson Cancer Research Center | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |
| US11332713B2 (en) | 2016-11-16 | 2022-05-17 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| KR20250072712A (ko) * | 2016-12-02 | 2025-05-26 | 앤젤레스 테라퓨틱스, 인코포레이티드 | 합성 면역 수용체 및 이의 사용 방법 |
| US11566061B2 (en) | 2017-01-05 | 2023-01-31 | Fred Hutchinson Cancer Center | Systems and methods to improve vaccine efficacy |
| US11603519B2 (en) * | 2017-02-06 | 2023-03-14 | National Cancer Center Japan | T-cell receptor |
| CA3055983A1 (en) * | 2017-03-15 | 2018-09-20 | Fred Hutchinson Cancer Research Center | High affinity mage-a1-specific tcrs and uses thereof |
| JP2020511136A (ja) | 2017-03-17 | 2020-04-16 | フレッド ハッチンソン キャンサー リサーチ センター | 免疫調節性融合タンパク質およびその使用 |
| AU2018259029B2 (en) | 2017-04-24 | 2024-03-07 | Fondazione Centro San Raffaele | TCR and peptides |
| NL2019156B1 (en) * | 2017-06-30 | 2019-01-10 | Academisch Ziekenhuis Leiden H O D N Leids Univ Medisch Centrum | Treatment of haematological malignancies |
| EP4327819A3 (en) * | 2017-06-30 | 2024-05-29 | Academisch Ziekenhuis Leiden (H.O.D.N. Leids Universitair Medisch Centrum) | Treatment of haematological malignancies |
| CN107267463A (zh) * | 2017-08-23 | 2017-10-20 | 安徽惠恩生物科技股份有限公司 | 一种针对乳腺癌的Car‑NK细胞制备方法 |
| ES2915576T3 (es) | 2017-09-19 | 2022-06-23 | Tropic Biosciences Uk Ltd | Modificación de la especificidad de moléculas de ARN no codificantes de plantas para silenciar la expresión génica |
| AU2018345539A1 (en) | 2017-10-03 | 2020-04-16 | Editas Medicine, Inc. | HPV-specific binding molecules |
| CN109777778B (zh) * | 2017-11-14 | 2023-07-18 | 中国科学院广州生物医药与健康研究院 | 一种基因改造的γδT细胞 |
| BR112020011469A2 (pt) | 2017-12-21 | 2020-11-24 | F. Hoffmann-La Roche Ag | anticorpos, molécula de ligação ao antígeno biespecífica, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, uso do anticorpo, método de tratamento de uma doença e invenção |
| US12280092B2 (en) | 2018-01-05 | 2025-04-22 | Nantbio, Inc. | Reprogrammed T cell-like NK cells |
| CA3093915A1 (en) | 2018-03-15 | 2019-09-19 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| BR112020018658A2 (pt) | 2018-03-15 | 2020-12-29 | KSQ Therapeutics, Inc. | Composições de regulação gênica e métodos para imu-noterapia aprimorada |
| DE102018108612A1 (de) * | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| CA3095027A1 (en) * | 2018-04-05 | 2019-10-10 | Juno Therapeutics, Inc. | T cell receptors and engineered cells expressing same |
| JP7630280B2 (ja) * | 2018-04-05 | 2025-02-17 | ジュノー セラピューティクス インコーポレイテッド | 組換え受容体を発現するｔ細胞、関連ポリヌクレオチド、および方法 |
| US20220403001A1 (en) | 2018-06-12 | 2022-12-22 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| CN112585162B (zh) * | 2018-08-06 | 2025-01-28 | 基因医疗免疫疗法有限责任公司 | Ha-1特异性t细胞受体及其用途 |
| US20210317184A1 (en) * | 2018-09-05 | 2021-10-14 | GlaxoSmithKline Intellectual Property Devolopment Limited | T cell modification |
| US12440546B2 (en) | 2018-10-05 | 2025-10-14 | International Institute Of Cancer Immunology, Inc. | Composition for preventing or treating benign tumor |
| SG11202103571XA (en) | 2018-10-16 | 2021-05-28 | Intellia Therapeutics Inc | Compositions and methods for immunotherapy |
| GB201817821D0 (en) * | 2018-10-31 | 2018-12-19 | Ospedale San Raffaele Srl | TCR and peptides |
| US12448430B2 (en) | 2019-03-11 | 2025-10-21 | Fred Hutchinson Cancer Center | High avidity WT1 T cell receptors and uses thereof |
| CN111714618B (zh) * | 2019-03-22 | 2024-07-12 | 香雪生命科学技术（广东）有限公司 | T细胞和高亲和力pd-1融合蛋白的组合 |
| EP3750547A1 (en) | 2019-06-13 | 2020-12-16 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz | Modified nk-92 cells, and therapeutic and diagnostic uses thereof |
| WO2021034976A1 (en) * | 2019-08-20 | 2021-02-25 | Fred Hutchinson Cancer Research Center | T-cell immunotherapy specific for wt-1 |
| EP4086281A4 (en) * | 2019-12-30 | 2024-02-14 | China Immunotech (Beijing) Biotechnology Co., Ltd | IMPROVED STAR T CELL RECEPTOR AND ITS APPLICATION |
| CN114106144B (zh) * | 2020-08-27 | 2024-01-26 | 溧阳瑅赛生物医药有限公司 | 识别hla-a*02/wt1靶点的tcr及其应用 |
| WO2022132836A2 (en) | 2020-12-14 | 2022-06-23 | Fred Hutchinson Cancer Research Center | Compositions and methods for cellular immunotherapy |
| JP2024514705A (ja) * | 2021-04-21 | 2024-04-02 | オックスフォード ユニヴァーシティ イノヴェーション リミテッド | 方法及び組成物 |
| EP4340853A4 (en) * | 2021-05-20 | 2025-05-07 | Washington University | Neuroprotective compositions and methods |
| CA3225252A1 (en) | 2021-07-14 | 2023-01-19 | Jordan JARJOUR | Engineered t cell receptors fused to binding domains from antibodies |
| CN113773378B (zh) * | 2021-10-14 | 2023-11-03 | 深圳大学总医院 | T细胞受体及其应用 |
| EP4423144A4 (en) * | 2021-10-29 | 2025-10-08 | Yafei Hou | T CELL RECEPTOR RECOGNIZING THE S37F MUTATION IN CTNNB1 AND ITS USE |
| JP2025513801A (ja) | 2022-04-08 | 2025-04-30 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 多部位受容体及びシグナル伝達複合体 |
| JP2025527575A (ja) | 2022-08-18 | 2025-08-22 | イミュノコア リミテッド | Ｍａｇｅ ａ４に特異的なｔ細胞受容体融合タンパク質 |
| EP4609202A2 (en) * | 2022-10-28 | 2025-09-03 | Memorial Sloan-Kettering Cancer Center | T cell receptors targeting ewsr1-wt1 fusion protein and uses thereof |
| WO2024178397A2 (en) | 2023-02-24 | 2024-08-29 | Elevatebio Technologies, Inc. | Modified immune effector cells and methods of use |
| WO2025007073A2 (en) | 2023-06-29 | 2025-01-02 | Dispatch Biotherapeutics, Inc. | Synthetic cytokine receptors |
| WO2025240518A1 (en) | 2024-05-14 | 2025-11-20 | Dispatch Biotherapeutics, Inc. | Modified lentiviral transfer plasmids |
| GB202406990D0 (en) * | 2024-05-16 | 2024-07-03 | Univ Oxford Innovation Ltd | T cell receptors and uses thereof |
| WO2025245169A1 (en) | 2024-05-21 | 2025-11-27 | Fred Hutchinson Cancer Center | Immunotherapy cells equipped with a collagen-targeting payload |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| CN1178956C (zh) | 1998-07-31 | 2004-12-08 | 杉山治夫 | 基于癌抑制基因wt1的产物的癌抗原 |
| GB9823897D0 (en) | 1998-11-02 | 1998-12-30 | Imp College Innovations Ltd | Immunotherapeutic methods and molecules |
| JP4611022B2 (ja) | 2002-09-12 | 2011-01-12 | 株式会社癌免疫研究所 | 癌抗原ペプチド製剤 |
| US7575925B2 (en) | 2002-12-10 | 2009-08-18 | Sunnybrook Health Sciences Centre | Cell preparations comprising cells of the T cell lineage and methods of making and using them |
| ES2556232T3 (es) | 2004-03-31 | 2016-01-14 | International Institute Of Cancer Immunology, Inc. | Péptidos antigénicos del cáncer derivados de WT1 |
| WO2006076678A2 (en) | 2005-01-13 | 2006-07-20 | The Johns Hopkins University | Prostate stem cell antigen vaccines and uses thereof |
| CN102272153B (zh) | 2008-11-24 | 2015-04-15 | 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 | 高亲和力t细胞受体及其应用 |
| EP2258719A1 (en) | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
| GB0911566D0 (en) * | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| US9586997B2 (en) * | 2010-09-20 | 2017-03-07 | Biontech Cell & Gene Therapies Gmbh | Antigen-specific T cell receptors and T cell epitopes |
| CN107557334B (zh) * | 2012-05-03 | 2021-06-25 | 弗雷德哈钦森癌症研究中心 | 增强亲和力的t细胞受体及其制备方法 |
| MX2015000979A (es) * | 2012-07-27 | 2015-11-23 | Univ Illinois | Ingenieria de receptores de celulas t. |
| DK2951202T3 (da) * | 2013-01-29 | 2020-07-13 | Max Delbrueck Centrum Fuer Molekulare Medizin Mdc Berlin Buch | Mage-a1-genkendende bindingsmolekyler med høj aviditet |
-
2015
- 2015-07-30 ES ES15753531T patent/ES2841274T3/es active Active
- 2015-07-30 US US14/813,782 patent/US10538572B2/en active Active
- 2015-07-30 EP EP15753531.1A patent/EP3177314B1/en active Active
- 2015-07-30 WO PCT/US2015/042986 patent/WO2016022400A1/en not_active Ceased
- 2015-07-30 CN CN201580049647.6A patent/CN107074970B/zh active Active
- 2015-07-30 JP JP2017505792A patent/JP6712261B2/ja active Active
- 2015-07-30 CA CA2956545A patent/CA2956545A1/en active Pending
-
2018
- 2018-07-30 JP JP2018142600A patent/JP2018183175A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017523784A5 (enExample) | ||
| JP7157839B2 (ja) | 癌治療のための免疫療法とサイトカイン制御療法との組み合わせ | |
| JP7527049B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| JP7223055B2 (ja) | 癌治療のための併用免疫療法及びサイトカイン制御療法 | |
| Di et al. | Combined adjuvant of poly I: C improves antitumor effects of CAR-T cells | |
| Dotti et al. | Design and development of therapies using chimeric antigen receptor‐expressing T cells | |
| Baxevanis et al. | Cancer immunotherapy | |
| JP2020509767A5 (enExample) | ||
| Kershaw et al. | Gene-engineered T cells for cancer therapy | |
| Helmy et al. | Cancer immunotherapy: accomplishments to date and future promise | |
| Redeker et al. | Improving adoptive T cell therapy: the particular role of T cell costimulation, cytokines, and post-transfer vaccination | |
| Geller et al. | Use of allogeneic NK cells for cancer immunotherapy | |
| Bernatchez et al. | Advances in the treatment of metastatic melanoma: adoptive T-cell therapy | |
| JP2016520074A5 (enExample) | ||
| JP2017531687A5 (enExample) | ||
| WO2017159736A1 (ja) | 免疫機能制御因子を発現する免疫担当細胞及び発現ベクター | |
| WO2018193119A1 (en) | Gene therapy | |
| JP2020533962A5 (enExample) | ||
| Danhof et al. | CARs and other T cell therapies for MM: the clinical experience | |
| Dhodapkar et al. | Hematologic malignancies: plasma cell disorders | |
| Reynders et al. | Radiotherapy and immunotherapy: improving cancer treatment through synergy | |
| Brayer et al. | Developing strategies in the immunotherapy of leukemias | |
| Garber et al. | Adoptive T-cell therapy for Leukemia | |
| Hanagiri et al. | Retracted: Antitumor activity of human γδ T cells transducted with CD 8 and with T‐cell receptors of tumor‐specific cytotoxic T lymphocytes | |
| Croce et al. | New immunotherapeutic strategies for the treatment of neuroblastoma |